C-CAMP – BNV Innovation Hub (CBIH)
C-CAMP and Japanese Venture Capital Firm, Beyond Next Ventures (BNV) institutes an Innovation Hub to fund and foster early stage innovations in India
Now accepting applications from startups in medtech and medical devices
To apply write to cbih[at]ccamp.res.in by October 15th, 2020
C-CAMP has recently collaborated with Beyond Next Ventures (BNV), one of the leading independent accelerators in Japan dedicated to incubation investment in technology start-ups. The broad aim of this collaboration is to encourage and promote the best deep science innovations in the field of Life Sciences and Biotechnology in India & Japan.
The two organizations intend to create the C-CAMP – BNV Innovation Hub (CBIH) which will largely focus on facilitating Japanese investment of up to 5 million USD in Indian start-ups working on exciting technologies in the Life Sciences and Biotech domain through a jointly managed fund. This hub also aims to support start-ups in both the regions through exchange of human resources and technologies and through other facilitation programs and events to connect skilled talent, entrepreneurs and other stakeholders in both regions.
Activities under C-CAMP – BNV Innovation Hub (CBIH):
- CBIH Funding Program
Through the CBIH, C-CAMP and BNV will fund and mentor deep science innovations with global impact. CBIH promises investments of up to $5 Million in Indian startups working in the life sciences and biotech domain.
- Mutual acceptance of innovators and start-ups into each other's programs
In order to facilitate collaborations between the 2 regions, C-CAMP and BNV will accept start-ups from both regions into their incubation and acceleration programs.
- Annual CBIH Hackathons
With the objective of increasing work opportunities for Indian skilled talent and technologists and assisting expansion of Japanese startups into India, annual hackathon events will be organized to facilitate these connections.
Biomoneta Research Pvt Ltd
Biomoneta's ZeBox is an air decontamination technology that traps & kills microbes which cause disease and product contamination. Their continuous-use, no-touch devices are built around this disruptive patent-pending technology that finds application in multiple environments requiring clean, germ-free air can be used in ICUs and sick rooms. The device exploits the electrical properties of bacteria, novel antimicrobial and engineering design; and is meant to be a bedside unit that both prevents an infectious patient from spreading the disease and protects a naïve patient from acquiring an infection. They have secured follow-on funding from angel investors, SBIRI and Idea2POC schemes.